The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial.
 
Benjamin Besse
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); cergentis (Inst); Chugai Pharma (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Turning Point Therapeutics (Inst)
 
Rosario Garcia Campelo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Takeda
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Roche/Genentech
 
Manuel Cobo-Dols
No Relationships to Disclose
 
Elisabeth Anne Quoix
No Relationships to Disclose
 
Anne Madroszyk
No Relationships to Disclose
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Janssen; Lilly; Merck Serono; MSD Oncology; Novartis; Peptomyc; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; CME outfitters; Lilly; Medscape; Merck Sharp & Dohme; PeerVoice; Pfizer; Roche; Takeda
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRÍFOLS
 
Federico Cappuzzo
Honoraria - AstraZeneca/MedImmune; Lilly; MSD Oncology; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; MSD Oncology; pfizer; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - OSE Immunotherapeutics
 
Fabrice Denis
Stock and Other Ownership Interests - Kelindi (Inst)
Honoraria - AstraZeneca; IPSEN; MSD; Pfizer/EMD Serono; ROCHE; Takeda
Consulting or Advisory Role - SIVAN Innovation (Inst)
Other Relationship - Chugai Pharma; Ferring; Ipsen; Janssen-Cilag; Merck Serono; Novartis; Takeda
 
Werner Hilgers
Honoraria - MSD Oncology
Consulting or Advisory Role - AstraZeneca; Janssen
 
Giampiero Romano
No Relationships to Disclose
 
Didier Debieuvre
Honoraria - AstraZeneca; BMS France; GlaxoSmithKline; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; BMS France; MSD Oncology; Novartis; OSE Immunotherapeutics; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS france (Inst); Boehringer Ingelheim (Inst); Chiesi (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS france; BMS france; BMS France; Boehringer Ingelheim; Boehringer Ingelheim France; Lilly (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; novartis France; Pfizer; Roche; Roche; Takeda
 
Domenico Galetta
Speakers' Bureau - Astra Zeneca Italia; BMS Italy; Lilly; MSD Oncology; Roche
 
Editta Baldini
No Relationships to Disclose
 
Santiago Viteri Ramirez
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Merck KGaA; Puma Biotechnology; Reddy Pharma Iberia; Roche; Takeda
Speakers' Bureau - AstraZeneca Spain; Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Merck KGaA; Merck KGaA; MSD; Roche
 
Minh Duc Phan
No Relationships to Disclose
 
Wolfgang Schuette
Honoraria - MSD; Novartis; Roche
Consulting or Advisory Role - MSD; Novartis; Roche
 
Alona Zer
Stock and Other Ownership Interests - Nixio
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche; Takeda
Research Funding - Bristol Myers Squibb Foundation (Inst)
 
Berangere Vasseur
Employment - OSE Immunotherapeutics
Stock and Other Ownership Interests - OSE Immunotherapeutics
Patents, Royalties, Other Intellectual Property - Patent "USES OF ANTI-SIRPa ANTIBODIES IN THE TREATMENT OF CANCER"
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; PFIZER; Roche/Genentech; Seagen; Takeda
Consulting or Advisory Role - Karyopharm Therapeutics; Regeneron
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Giuseppe Giaccone
Consulting or Advisory Role - Daiichi; Eisai; Janssen Oncology; Novartis; Radiomics; Sanofi; Sanofi/Regeneron; Spectrum Pharmaceuticals
Research Funding - Cantargia AB (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst)